Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Nov;35(11):2440–2443. doi: 10.1128/aac.35.11.2440

Inhibitory effects of acyclic nucleoside phosphonate analogs, including (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, on Epstein-Barr virus replication.

J C Lin 1, E De Clercq 1, J S Pagano 1
PMCID: PMC245402  PMID: 1666500

Abstract

(S)-9-(3-Hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA], (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)-2,6-diaminopurine [(S)-HPMPDAP], cyclic (S)-HPMPA [(S)-cHPMPA], 9-(2-phosphonylmethoxyethoxyethyl)-2,6-diaminopurine (PMEDAP), and (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] were examined for their inhibitory effects on Epstein-Barr virus (EBV) replication. The 50% effective concentrations for inhibition of viral DNA replication were 0.16, 0.03, 2.0, 1.5, and 0.08 microM for PMEDAP, (S)-HPMPC, (S)-HPMPDAP, (S)-cHPMPA, and (S)-HPMPA, respectively. The relative efficacies based on the in vitro therapeutic index was (S)-HPMPC (5,000) greater than PMEDAP (1,000) = (S)-HPMPA (1,000) greater than (S)-cHPMPA (136) greater than (S)-HPMPDAP (78). Certain ratios of combinations of (S)-HPMPC with 3'-azido-3'-deoxythymidine produced a synergistic inhibitory effect on EBV genome replication, but others exhibited an antagonistic effect. These results indicate that this series of acyclic nucleoside phosphonate analogs, and in particular (S)-HPMPC, are potent and selective anti-EBV agents in vitro.

Full text

PDF
2440

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beauchamp L. M., Serling B. L., Kelsey J. E., Biron K. K., Collins P., Selway J., Lin J. C., Schaeffer H. J. Effect of acyclic pyrimidines related to 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine on herpesviruses. J Med Chem. 1988 Jan;31(1):144–149. doi: 10.1021/jm00396a021. [DOI] [PubMed] [Google Scholar]
  2. De Clercq E., Holý A., Rosenberg I., Sakuma T., Balzarini J., Maudgal P. C. A novel selective broad-spectrum anti-DNA virus agent. Nature. 1986 Oct 2;323(6087):464–467. doi: 10.1038/323464a0. [DOI] [PubMed] [Google Scholar]
  3. De Clercq E., Sakuma T., Baba M., Pauwels R., Balzarini J., Rosenberg I., Holý A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 1987 Dec;8(5-6):261–272. doi: 10.1016/s0166-3542(87)80004-9. [DOI] [PubMed] [Google Scholar]
  4. Evans A. S. Hypothesis: the pathogenesis of AIDS. Activation of the T- and B-cell cascades. Yale J Biol Med. 1984 May-Jun;57(3):317–327. [PMC free article] [PubMed] [Google Scholar]
  5. Lin J. C., DeClercq E., Pagano J. S. Novel acyclic adenosine analogs inhibit Epstein-Barr virus replication. Antimicrob Agents Chemother. 1987 Sep;31(9):1431–1433. doi: 10.1128/aac.31.9.1431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Lin J. C., Sista N. D., Besençon F., Kamine J., Pagano J. S. Identification and functional characterization of Epstein-Barr virus DNA polymerase by in vitro transcription-translation of a cloned gene. J Virol. 1991 May;65(5):2728–2731. doi: 10.1128/jvi.65.5.2728-2731.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lin J. C., Smith M. C., Pagano J. S. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. J Virol. 1984 Apr;50(1):50–55. doi: 10.1128/jvi.50.1.50-55.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lin J. C., Zhang Z. X., Chou T. C., Sim I., Pagano J. S. Synergistic inhibition of Epstein-Barr virus: transformation of B lymphocytes by alpha and gamma interferon and by 3'-azido-3'-deoxythymidine. J Infect Dis. 1989 Feb;159(2):248–254. doi: 10.1093/infdis/159.2.248. [DOI] [PubMed] [Google Scholar]
  9. Pauwels R., Balzarini J., Schols D., Baba M., Desmyter J., Rosenberg I., Holy A., De Clercq E. Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother. 1988 Jul;32(7):1025–1030. doi: 10.1128/aac.32.7.1025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Sandstrom E. G., Kaplan J. C., Byington R. E., Hirsch M. S. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet. 1985 Jun 29;1(8444):1480–1482. doi: 10.1016/s0140-6736(85)92255-x. [DOI] [PubMed] [Google Scholar]
  11. Smith M. S., Brian E. L., De Clercq E., Pagano J. S. Susceptibility of human immunodeficiency virus type 1 replication in vitro to acyclic adenosine analogs and synergy of the analogs with 3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother. 1989 Sep;33(9):1482–1486. doi: 10.1128/aac.33.9.1482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sundqvist V. A., Linde A., Kurth R., Werner A., Helm E. B., Popovic M., Gallo R. C., Wahren B. Restricted IgG subclass responses to HTLV-III/LAV and to cytomegalovirus in patients with AIDS and lymphadenopathy syndrome. J Infect Dis. 1986 May;153(5):970–973. doi: 10.1093/infdis/153.5.970. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES